Freyya

Based in the US, Freyya, operates as a provider of monitoring and biofeedback solutions and services. Based in Salt Lake City, US and founded in 2024, Freyya engages in developing innovative health solutions. Freyya is developing a groundbreaking pelvic floor monitoring and rehabilitation device designed specifically for individuals experiencing pelvic floor dysfunction. The Freyya™ device features a tampon-like biosensor that allows users to monitor their pelvic floor physical therapy in real-time, suitable for various activities.

It provides direct feedback to users and remote tracking capabilities for healthcare providers, facilitating ongoing care. The device aims to empower women by addressing pelvic floor disorders, which affect a significant portion of the female population. Currently, the Freyya™ device is in development and is not available for sale; its client base primarily consists of healthcare professionals, including urogynecologists, OB/GYNs, and physical therapists. Freyya operates within a subscription-based revenue model tailored for healthcare providers and clinicians.

Once the Freyya™ device receives regulatory approvals, it is expected to generate revenue through partnerships with medical professionals who will integrate the device into their practice. These partnerships may involve structured agreements for device usage alongside ongoing training and support for practitioners. The company anticipates sales from individual consumers once the product is commercially available, positioning itself for both direct-to-consumer sales and B2B transactions with healthcare facilities. The company plans to utilize the funding raised in September 2026 to support its commercialization and technology development initiatives.